These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 29759929)

  • 1. Entacapone and prostate cancer in Parkinson's disease patients: A large Veterans Affairs healthcare system study.
    Major JM; Dong D; Cunningham F; By K; Hur K; Shih DC; Jiang R; Podskalny GD; Wei X; Pinheiro S; Bird ST; Keeton S; Graham DJ
    Parkinsonism Relat Disord; 2018 Aug; 53():46-52. PubMed ID: 29759929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entacapone and prostate cancer risk in patients with Parkinson's disease.
    Korhonen P; Kuoppamäki M; Prami T; Hoti F; Christopher S; Ellmén J; Aho V; Vahteristo M; Pukkala E; Haukka J
    Mov Disord; 2015 Apr; 30(5):724-8. PubMed ID: 25639262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
    Graham DJ; Williams JR; Hsueh YH; Calia K; Levenson M; Pinheiro SP; Macurdy TE; Shih D; Worrall C; Kelman JA
    Mov Disord; 2013 Apr; 28(4):490-7. PubMed ID: 23443994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early versus delayed initiation of entacapone in levodopa-treated patients with Parkinson's disease: a long-term, retrospective analysis.
    Nissinen H; Kuoppamäki M; Leinonen M; Schapira AH
    Eur J Neurol; 2009 Dec; 16(12):1305-11. PubMed ID: 19570145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease.
    Delea TE; Thomas SK; Hagiwara M; Mancione L
    Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off.
    Kuoppamäki M; Leinonen M; Poewe W
    J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study.
    Destée A; Rérat K; Bourdeix I
    Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.
    Kupsch A; Trottenberg T; Bremen D
    Curr Med Res Opin; 2004 Jan; 20(1):115-20. PubMed ID: 14741081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).
    Poewe WH; Deuschl G; Gordin A; Kultalahti ER; Leinonen M;
    Acta Neurol Scand; 2002 Apr; 105(4):245-55. PubMed ID: 11939936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis.
    Li J; Lou Z; Liu X; Sun Y; Chen J
    Eur Neurol; 2017; 78(3-4):143-153. PubMed ID: 28813703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
    Durif F; Devaux I; Pere JJ; Delumeau JC; Bourdeix I;
    Eur Neurol; 2001; 45(2):111-8. PubMed ID: 11244274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study.
    Zijlmans JC; Debilly B; Rascol O; Lees AJ; Durif F
    Mov Disord; 2004 Sep; 19(9):1006-1011. PubMed ID: 15372589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entacapone: prostate cancer?
    Prescrire Int; 2010 Oct; 19(109):217. PubMed ID: 21188808
    [No Abstract]   [Full Text] [Related]  

  • 16. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sleep attacks in Parkinson's disease induced by Entacapone, a COMT-inhibitor.
    Santens P
    Fundam Clin Pharmacol; 2003 Feb; 17(1):121-3. PubMed ID: 12588639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
    Brooks DJ; Sagar H;
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1071-9. PubMed ID: 12876237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entacapone. A review of its use in Parkinson's disease.
    Holm KJ; Spencer CM
    Drugs; 1999 Jul; 58(1):159-77. PubMed ID: 10439935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off .
    Jog M; Panisset M; Suchowersky O; Réhel B; Schecter R
    Curr Med Res Opin; 2008 Nov; 24(11):3207-15. PubMed ID: 18922214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.